<DOC>
	<DOCNO>NCT02599207</DOCNO>
	<brief_summary>This study single site , phase I , prospective study safety intravenous sibling cord blood infusion 15 child age 1-6 year Cerebral Palsy ( CP ) . All subject treat sibling cord blood cell . The first six receive cord blood cell HLA-matched sibling . The following nine subject receive cord blood cell HLA-mismatched ( ≥3/6 match ) match sibling . The duration study participation six month time cord blood infusion .</brief_summary>
	<brief_title>Assessment Safety Allogeneic Umbilical Cord Blood Infusions Children With Cerebral Palsy</brief_title>
	<detailed_description>This study phase I , prospective , open-label trial design assess safety single allogeneic sibling cord blood infusion young child cerebral palsy . Children age one six year uncomplicated cerebral palsy available HLA match haploidentical , qualified , sibling cord blood unit eligible participate . All participant receive single intravenous infusion allogeneic sibling cord blood . All participant initial clinical evaluation verify diagnosis cerebral palsy determine eligibility . The main endpoint safety , acute infusion reaction well incidence infection graft versus host disease assess . Functional outcome measure , describe , assessed baseline six month post sibling cord blood infusion describe .</detailed_description>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<criteria>1 . Age ≥12 month ≤ 6 year time CB infusion . 2 . Diagnosis : Cerebral palsy diplegia , hemiplegia , quadriplegia . 3 . Performance status : Bilateral cerebral palsy ( diplegia quadraplegia ) : Gross Motor Function Classification Score level II IV , Gross Motor Function Classification Score level I , age ≥ 2 year Hemiplegia : Gross Motor Function Classification Score level II IV minimal functional capability affect upper extremity . A subject classified GMFCS level I significant upper extremity impairment eligible affected upper extremity use assist . 4. Review brain imaging ( obtain standard care prior study entry ) suggest genetic condition brain malformation . 5 . Suitably match sibling donor CB unit ( see section 6.2 matching detail ) available private public cord blood bank minimum total nucleate cell dose ≥ 2.5 x 107 cells/kilogram . 6 . Legal authorize representative consent . 1 . Available qualified autologous cord blood unit 2 . Autism autistic spectrum disorder without motor disability . 3 . Hypsarrhythmia . 4 . Intractable seizure cause epileptic encephalopathy . 5 . Evidence progressive neurologic disease . 6 . Has active , uncontrolled systemic infection documentation HIV+ status . 7 . Known genetic disease phenotypic evidence genetic disease physical exam . 8 . Concurrent genetic acquire disease comorbidity ( y ) could require future allogeneic stem cell transplant . 9 . Requires ventilatory support , include home ventilator , CPAP , BiPAP , supplemental oxygen . 10 . Impaired renal liver function determine serum creatinine &gt; 1.5mg/dL and/or total bilirubin &gt; 1.3mg/dL except patient know Gilbert 's disease . 11 . Possible immunosuppression , define WBC &lt; 3,000 cells/mL absolute lymphocyte count ( ALC ) normal age abnormal Tcell subset . 12 . Patient 's medical condition permit safe travel . 13 . Previously receive form cellular therapy .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>